More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.01B
EPS
-1.93
P/E ratio
--
Price to sales
8.89
Dividend yield
--
Beta
0.859015
Previous close
$26.42
Today's open
$26.39
Day's range
$25.91 - $26.82
52 week range
$12.65 - $28.89
show more
CEO
Xingjuan Chao
Employees
327
Headquarters
Sunnyvale, CA
Exchange
Nasdaq Global Select
Shares outstanding
38835010
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
CeriBell Q3 Earnings Call Highlights
CeriBell NASDAQ: CBLL reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring Solution and introduce its next-generation Omni hardware platform in 2027.
MarketBeat • Nov 4, 2026

CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript
CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Ceribell Reports Third Quarter 2026 Financial Results
SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 3, 2026

Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics
The headline numbers for CeriBell, Inc. (CBLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 4, 2026

CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.37 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the commercial launch of its delirium monitoring solution on its point-of-care brain monitoring platform.
GlobeNewsWire • Nov 2, 2026

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City. The fireside chat will take place on Wednesday, November 11, 2026, at 7:00 a.m. Pacific Standard Time / 10:00 a.m. Eastern Standard Time.
GlobeNewsWire • Oct 28, 2026

Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, November 3, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 3, 2026.
GlobeNewsWire • Oct 20, 2026

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
SUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Ceribell System that makes it easier and faster for clinicians to interpret longitudinal brain activity and make appropriate clinical decisions.1 Brain monitoring with electroencephalography (EEG) can generate hours of complex data that can be difficult to interpret in a timely manner.
GlobeNewsWire • Sep 30, 2026

CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
MarketBeat • Aug 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell CeriBell Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.